A5020352485- Pancreatic and Hepatic Oncology Research
- Cancer Genomics and Diagnostics
- Electrolyte and hormonal disorders
- Pharmacological Effects and Toxicity Studies
- Diet and metabolism studies
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Colorectal Cancer Treatments and Studies
- COVID-19 and healthcare impacts
- Lung Cancer Treatments and Mutations
- Economic and Financial Impacts of Cancer
- Hepatocellular Carcinoma Treatment and Prognosis
- COVID-19 Clinical Research Studies
- Lung Cancer Research Studies
- Genetic factors in colorectal cancer
- Colorectal Cancer Screening and Detection
- Cancer Treatment and Pharmacology
- Viral-associated cancers and disorders
- Parkinson's Disease Mechanisms and Treatments
- Hepatitis C virus research
- Gallbladder and Bile Duct Disorders
- Health Systems, Economic Evaluations, Quality of Life
- BRCA gene mutations in cancer
- Renal cell carcinoma treatment
- Cancer-related molecular mechanisms research
- Liver Disease Diagnosis and Treatment
Beth Israel Deaconess Medical Center
2016-2025
Harvard University
2017-2025
Antwerp University Hospital
2024
Massachusetts General Hospital
2018-2023
Center for Assessment
2018-2023
Beth Israel Deaconess Hospital
2020-2021
University of Massachusetts Chan Medical School
2010
Washington University in St. Louis
1998
Abstract Purpose: Pancreatic ductal adenocarcinoma (PDAC) remains a significant health issue. For most patients, there are no options for targeted therapy, and existing treatments limited by toxicity. The HOPE trial (Harnessing Organoids PErsonalized Therapy) was pilot feasibility aiming to prospectively generate patient-derived organoids (PDO) from patients with PDAC test their drug sensitivity correlation clinical outcomes. Experimental Design: PDOs were established heterogeneous...
Background/Aims: People with disability have higher rates of cancer, excluding skin compared people without disability. Food and Drug Administration draft guidelines from 2024 address use performance status criteria to determine eligibility for clinical trials, advocating less restrictive thresholds. We examined the exclusion trials based on other criteria. Methods: reviewed in approved interventional Phase III IV oncology listed ClinicalTrails.gov between 1 January 2019 31 December 2023....
BACKGROUND The objective of this study was to investigate the prevalence pathogenic germline variants (PGVs) in 32 cancer susceptibility genes individuals with newly diagnosed pancreatic ductal adenocarcinoma (PDAC). A key secondary evaluate how often PGVs would have been undetected existing genetic testing criteria. METHODS From May 2016 through 2017, multicenter cohort enrolled consecutive patients aged 18 89 years histologically confirmed PDAC within previous 12 weeks. Demographics,...
538 Background: Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related deaths and has been associated with significant patient (pt) financial liability, however no study yet examined pt-reported measures toxicity (FT) in this population. We sought to assess FT newly diagnosed HCC identify pt-, disease-, treatment-related factors FT. Methods: Pts were recruited prior treatment initiation during their initial visit at multidisciplinary liver cancer clinic tertiary care center...
717 Background: SN-38, the active metabolite of irinotecan, is cleared by liver enzyme uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) and biliary excretion. UGT1A1*28 (genotype 7/7) homozygosity associated with reduced activity UGT1A1 a recommendation for dose adjustment non-liposomal component FOLFIRINOX regimen. In this post-hoc analysis, we analyzed impact on incidence profile treatment-emergent adverse events (TEAEs) among patients enrolled in NAPOLI 3 (NCT04083235). Methods:...
BACKGROUND: Psychiatric and neuropsychological side effects of subthalamic nucleus (STN) stimulation have been increasingly recognized. Most programming regimens focus on contacts 0 1, whereas contact 3, which often is located near or in the zona incerta (ZI), usually not used. The question whether ZI may limit limbic has answered. OBJECTIVE: To examine short-term (contact 3) compared with STN using standard trajectories targeting as measured by motor functions. METHODS: Motor functions 11...
Abstract Background Treatment patterns for intrahepatic cholangiocarcinoma (ICC) and extrahepatic (ECC) differ, but limited studies exist comparing them. This study examines differences in molecular profiling rates treatment these populations, focusing on use of adjuvant, liver-directed, targeted, investigational therapies. Methods multicenter collaboration included patients with ICC or ECC treated at 1 8 participating institutions. Retrospective data were collected risk factors, pathology,...
Abstract Background The fluoropyrimidines, 5-fluorouracil (5-FU) and capecitabine, are commonly used chemotherapeutic agents that have been associated with coronary vasospasm. Methods In this retrospective case-control study, we identified patients at our institution who received 5-FU or capecitabine in 2018. We compared characteristics of experienced cardiotoxicity controls. described phenotypes outcomes cardiotoxic cases. Results 177 fluoropyrimidines. After adjudication, 4.5% the cohort...
TPS350 Background: Mutations in isocitrate dehydrogenase 1 (mIDH1) are found approximately 20-30% of patients with intrahepatic cholangiocarcinoma (CCA), and less commonly glioma, chondrosarcoma, other gastrointestinal malignancies. Despite documented clinical activity mIDH1 inhibition solid tumors, there no approved targeted therapies for this patient population. LY3410738 is a potent, selective, covalent inhibitor R132. differentiated from prior inhibitors by 1) its unique binding mode, 2)...
We evaluated the potential cost-effectiveness of combined magnetic resonance imaging (MRI) and endoscopic ultrasound (EUS) screening for pancreatic ductal adenocarcinoma (PDAC) among populations at high risk disease.
Randomized controlled studies have shown deep brain stimulation (DBS) to be an effective treatment for Parkinson's disease (PD). Outside of large-center studies, little is known about trends in DBS use the USA.We employ Nationwide Inpatient Sample look at changes utilization over time.We identified all individuals with PD (332.0) and essential tremor (ET) (333.1) who underwent (02.93) from 1998 2007. We examined demographics, hospital status, comorbidities, in-hospital systemic/technical...
Despite clinical studies with different mechanisms of action, no new systemic therapies were approved for hepatocellular carcinoma (HCC) between sorafenib in 2007 and regorafenib 2017. This is an area interest to improve outcomes quality life. Cabozantinib oral, small-molecule tyrosine kinase inhibitor that primarily targets MET, VEGFR2, AXL RET, additional effect on KIT FLT3. progressive metastatic medullary thyroid cancer previously treated renal cell carcinoma, development multiple solid...
Background Germline genetic testing currently is recommended for patients with pancreatic ductal adenocarcinoma (PDAC). In the current study, authors assessed how often results are communicated to first‐degree relatives within 3 months and emotional impact of on patients. Methods A total 148 who were newly diagnosed PDAC had undergone 32 cancer susceptibility genes at academic centers selected; 71% participated. Subjects completed Multidimensional Impact Cancer Risk Assessment (MICRA) a...
Abstract Background COVID‐19 infection delays therapy and in‐person evaluation for oncology patients, but clinic clearance criteria are not clearly defined. Methods We conducted a retrospective review of patients with at tertiary care center during the Delta Omicron waves compared strategies. Results Median by two consecutive negative tests was 32.0 days (Interquartile Range [IQR] 22.0–42.5, n = 153) prolonged in hematologic malignancy versus solid tumors (35.0 malignancy, 27.5 tumors, p...
PURPOSE Increased awareness of the distinct tumor biology for adolescents and young adults (AYAs) with cancer has led to improvement in outcomes this population. However, cholangiocarcinoma (CCA), a paucity data exist on AYA To our knowledge, we present largest study date disease biology, treatment patterns, survival CCA. METHODS A multi-institutional cohort patients CCA diagnosed intrahepatic (ICC) or extrahepatic (ECC) was used analysis. Retrospective chart review conducted who were 50...
Importance Systematic data on the association between anticancer therapies and thromboembolic events (TEEs) in patients with COVID-19 are lacking. Objective To assess therapy exposure within 3 months prior to TEEs following diagnosis cancer. Design, Setting, Participants This registry-based retrospective cohort study included who were hospitalized had active cancer laboratory-confirmed SARS-CoV-2 infection. Data accrued from March 2020 December 2021 analyzed October 2022. Exposure Treatments...
Abstract Objectives: Our study provides phase-specific cost estimates for pancreatic cancer based on stage and treatment. We compare treatment costs between the different phases within modality subgroups. Methods: cohort included 20,917 patients from Surveillance, Epidemiology, End Results (SEER)-Medicare database diagnosed 2000 2011. allocated into four of care-staging (or surgery), initial, continuing, terminal– calculated total, cancer-attributable, patient-liability in 2018 US dollars....
A woman in her 60s was diagnosed with a metastatic, unresectable rare histological type of liver cancer; combined hepatocellular cholangiocarcinoma. She had palliative chemotherapy, initially gemcitabine and cisplatin, then oxaliplatin, L-folinic acid fluorouracil. Both treatment strategies demonstrated disease progression, somatic mutation profiling revealed no actionable mutations. The patient started on immuno-oncology (IO) nivolumab ipilimumab, followed by maintenance nivolumab. has...
Advanced cholangiocarcinoma (CCA) is associated with considerable morbidity and mortality. Novel second-line treatments for advanced CCA underscore the need to understand treatment patterns economic burden of illness in clinical practice.This retrospective, claims-based study using Optum's de-identified Clinformatics® Data Mart Database [2007-2019] selected patients who experienced failure a line therapy containing either gemcitabine or fluorouracil. The index date was defined based on...